HISUN PHARM HANGZHOU vs Philips North America: FDA Enforcement Comparison

Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 1 for HISUN PHARM HANGZHOU.

HISUN PHARM HANGZHOU: 0 warning letters, 0 recalls, 1 approval record, 0 Form 483s.

Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.

Side by side

HISUN PHARM HANGZHOU — Warning letters0

Philips North America — Warning letters0

HISUN PHARM HANGZHOU — Recalls0

Philips North America — Recalls355

HISUN PHARM HANGZHOU — Approval records1

Philips North America — Approval records0

HISUN PHARM HANGZHOU — Form 483s0

Philips North America — Form 483s0

Timeline

HISUN PHARM HANGZHOU

Most recent FDA action: July 23, 2026

Full history →

Philips North America

Most recent FDA action: July 1, 2026

Full history →

Cite this comparison

Pre-formatted for a story, footnote, or reference list:

"HISUN PHARM HANGZHOU vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed July 29, 2026. https://argushq.ai/compare/hisun-pharm-hangzhou-vs-philips-north-america

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗